Skip to main
TNYA
TNYA logo

Tenaya Therapeutic (TNYA) Stock Forecast & Price Target

Tenaya Therapeutic (TNYA) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tenaya Therapeutics Inc is making significant strides in its preclinical stage, particularly with promising improvements in left ventricular posterior wall thickness (LVPWT) and left ventricular mass index (LVMI) as seen in its recent data readouts. The positive safety reviews from independent Data Safety and Monitoring Boards for ongoing trials of gene therapy programs TN-201 and TN-401 underscore the company's commitment to advancing its innovative treatments for heart disease. Furthermore, the encouraging cardiac biomarker trends and stable improvements in New York Heart Association (NYHA) classification among patients provide a strong foundation for a potentially accelerated approval pathway in the future.

Bears say

Tenaya Therapeutics Inc. faces significant challenges as it navigates the preclinical stage of its biotechnology development, with potential delays in transitioning its assets to clinical trials that may negatively affect market sentiment and lead to downward revisions of financial estimates. The company's reliance on adeno-associated virus (AAV) gene therapy technologies introduces complexity in manufacturing, increasing the risk of development and commercialization delays that could further constrain financial forecasts. Additionally, emerging safety signals related to immune reactions may impose limitations on dosing regimens, jeopardizing the efficacy and marketability of Tenaya's product candidates.

Tenaya Therapeutic (TNYA) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tenaya Therapeutic and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tenaya Therapeutic (TNYA) Forecast

Analysts have given Tenaya Therapeutic (TNYA) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Tenaya Therapeutic (TNYA) has a Strong Buy consensus rating as of Dec 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tenaya Therapeutic (TNYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.